Business Description
hVIVO PLC
ISIN : GB00B9275X97
Total Employee Number:
376Description
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.97 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | 12.34 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 2.35 | |||||
Beneish M-Score | -0.85 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.9 | |||||
3-Year EBITDA Growth Rate | -20.6 | |||||
3-Year Book Growth Rate | 23.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.58 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 100 | |||||
9-Day RSI | 100 | |||||
14-Day RSI | 99.83 | |||||
6-1 Month Momentum % | -64.13 | |||||
12-1 Month Momentum % | -64.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.63 | |||||
Quick Ratio | 1.59 | |||||
Cash Ratio | 0.81 | |||||
Days Inventory | 20.44 | |||||
Days Sales Outstanding | 39.91 | |||||
Days Payable | 32.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.46 | |||||
5-Year Yield-on-Cost % | 2.46 | |||||
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | -0.87 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.59 | |||||
Operating Margin % | -6.92 | |||||
Net Margin % | -12.81 | |||||
EBITDA Margin % | 2.56 | |||||
FCF Margin % | -33.88 | |||||
OCF Margin % | -30.83 | |||||
ROE % | -14.22 | |||||
ROA % | -7.3 | |||||
ROIC % | -5.48 | |||||
3-Year ROIIC % | -44.28 | |||||
ROC (Joel Greenblatt) % | -16.6 | |||||
ROCE % | -6.1 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 18.27 | |||||
PS Ratio | 1.01 | |||||
PB Ratio | 1.23 | |||||
Price-to-Tangible-Book | 2.19 | |||||
EV-to-EBIT | -13.87 | |||||
EV-to-Forward-EBIT | -11.43 | |||||
EV-to-EBITDA | 40.06 | |||||
EV-to-Forward-EBITDA | 44.03 | |||||
EV-to-Revenue | 1.03 | |||||
EV-to-Forward-Revenue | 0.95 | |||||
EV-to-FCF | -3.03 | |||||
Price-to-GF-Value | 0.44 | |||||
Price-to-Projected-FCF | 0.69 | |||||
Price-to-Median-PS-Value | 0.58 | |||||
Earnings Yield (Greenblatt) % | -7.21 | |||||
FCF Yield % | -33.36 |
hVIVO PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
hVIVO PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-23 17:00 | In 88 days | ||
| Second quarter earnings results for 2026 | 2026-09-23 | In 87 days | ||
| General meeting for 2025 | 2026-05-13 10:00 | 0.09 (+0.00%) | ||
| Annual report for 2025 | 2026-04-17 | 0.09 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-15 10:00 | 0.09 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-15 | 0.09 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-23 17:00 | 0.24 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-23 | 0.24 (+0.00%) | ||
| General meeting for 2024 | 2025-06-05 11:00 | 0.24 (+0.00%) | ||
| GBP 0.002000 Cash Dividend | 2025-05-15 | 0.24 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:OPORF
No articles.
Press Release
Articles on hVIVO PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers